Nyrada (ASX:NYR) ROIC %: -417.22% (As of Dec. 2025)


ASX:NYR Nyrada Inc ASX:NYR
25 GF Score
Price A$0.45
! 1 Warning Sign
View Full Analysis

What is Nyrada ROIC %?

Nyrada ASX:NYR +7.14% 25 ROIC % is -417.22% as of Dec. 2025. GuruFocus rates ASX:NYR with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Nyrada's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was -417.22%.

As of today (2026-06-30), Nyrada's WACC % is 4.02%. Nyrada's ROIC % is -572.25% (calculated using TTM income statement data). Nyrada earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Nyrada  (ASX:NYR) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Nyrada's WACC % is 4.02%. Nyrada's ROIC % is -572.25% (calculated using TTM income statement data). Nyrada earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Nyrada ROIC % Related Terms


Nyrada ROIC % Historical Data

* Premium members only.

The historical data trend for Nyrada's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada ROIC % Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROIC %
Get a 7-Day Free Trial -1,302.44 -620.45 -1,207.74 -789.14 -1,083.25

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -969.10 -1,407.68 -1,583.06 -1,285.60 -417.22

ASX:NYR vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, Nyrada's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nyrada ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's ROIC % distribution charts can be found below:

* The bar in red indicates where Nyrada's ROIC % falls into.


ASX:NYR
25GF Score
Nyrada Inc ASX:NYR
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada ROIC % Calculation

Nyrada's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2025 is calculated as:

ROIC % (A: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2024 ) + Invested Capital (A: Jun. 2025 ))/ count )
=-7.404 * ( 1 - 0% )/( (0.48 + 0.887)/ 2 )
=-7.404/0.6835
=-1,083.25 %

where

Nyrada's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-8.046 * ( 1 - 0% )/( (0.887 + 2.97)/ 2 )
=-8.046/1.9285
=-417.22 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -417.22% mean?
Nyrada (ASX:NYR) has a ROIC % of -417.22% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Nyrada and its competitors.
Is Nyrada's ROIC % too high?
Nyrada's current ROIC % is -417.22%. Overall, Nyrada has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's ROIC % compare to VRTX and REGN?
Nyrada's ROIC % of -417.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Nyrada and its competitors. Nyrada's current ROIC % is -417.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current ROIC % of -417.22%. The current ROIC % is -417.22%. Nyrada's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current ROIC % is -417.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
25GF Score

Get the complete analysis for ASX:NYR

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.45
Price